欧盟评估扩展使用经巴氏灭菌的嗜粘蛋白阿克曼菌作为新型食品的安全性

 　　  2025年9月25日，据欧盟食品安全局（EFSA）消息，欧盟营养、新型食品和食物过敏原（NDA）研究小组就扩展使用经巴氏灭菌的嗜粘蛋白阿克曼菌（pasteurised Akkermansia muciniphila）作为新型食品的安全性发表科学意见。 
　　部分原文报道如下：
 
　　Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on the safety of an extension of use of pasteurised Akkermansia muciniphila as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The extension pertains to the use of the NF in food supplements and Foods for Special Medical Purposes (FSMPs) for adolescents from 12 to < 18 years of age and to pregnant and lactating women. The maximum proposed daily doses of the NF correspond to about 4.8 × 10⁸ cells/kg bodyweight per day, which was the safe dose as established for the NF by the Panel in 2021. The newly identified toxicological and human studies with A. muciniphila from various strains, including the strain to which the NF belongs, do not raise safety concerns in view of the extension of use of the NF for adolescents from 12 years of age. However, no evidence was provided for the safety of the NF in pregnant and lactating women. The Panel concludes that the NF, pasteurised A. muciniphila, is safe at doses up to 2.1 × 10¹⁰ cells/day for adolescents from 12 to < 14 years and 3.0 × 10¹⁰ cells/day for adolescents from 14 years until < 18 years. The safety of the NF in pregnant and lactating women has not been established.